- Home
- / Adaptive Biotechnologies
Adaptive BiotechnologiesAdaptive Biotechnologies
Partners
125
FY, 2018
Revenue
$154.3 M
FY, 2021
Market Capitalization
$1.2 B
2022-11-18
Adaptive Biotechnologies Summary
Company summary
- Overview
- Adaptive Biotechnologies is a biotechnology company that focuses on adaptive immune systems. It develops a medicine platform that analyzes the genetic code of the immune system's defense against diseases. The company offers diagnosis and monitoring, and enables treatment of various diseases such as cancer, autoimmune disorders, and infectious diseases.
- Type
- Public
- Status
- Active
- Founded
- 2009
- HQ
- Seattle, WA, US | view all locations
- Website
- http://adaptivebiotech.com
- Cybersecurity rating
- ESG rating
Key people
Nancy Hill, Executive Vice President, Operations & Program Management
Harlan Robins, Chief Scientific Officer and Co-Founder
Chad Robins, Chief Executive Officer, Co-Founder, Chairman of the Board
Operating MetricsView all
Partners
125
FY, 2018
Immune Receptors Characteristics in Database
20B
FY, 2018
Product Lines
2
FY, 2018
LocationsView all
2 locations detected
Seattle, WA HQ
United States
1551 Eastlake Ave E #200
South San Francisco, CA
United States
2 Tower Pl UNIT 900
Adaptive Biotechnologies Financials
Summary financials
- Revenue (Q3, 2022)
- $47.8M
- Gross profit (Q3, 2022)
- $32.9M
- Net income (Q3, 2022)
- ($45.3M)
- EBIT (Q3, 2022)
- ($45.4M)
